IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
Provided By GlobeNewswire
Last update: Mar 13, 2025
NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2024.
Read more at globenewswire.com
